<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876200</url>
  </required_header>
  <id_info>
    <org_study_id>2006.437/30</org_study_id>
    <nct_id>NCT00876200</nct_id>
  </id_info>
  <brief_title>Efficacy of Minoxidil in Children With Williams-Beuren Syndrome</brief_title>
  <acronym>Williams</acronym>
  <official_title>The Efficacy of Minoxidil in Children With Williams-Beuren Syndrome: a Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Williams-Beuren syndrome (WBS) is a sporadic congenital disorder characterized by a
      multisystem developmental impairment. This syndrome is caused by a microdeletion in
      chromosome 7q11.23 that encompasses loss of the elastin locus.

      Elastin, which is part of the extracellular matrix, controls proliferation of vascular smooth
      muscle cells (VSMCs) and stabilizes arterial structure. Loss of elastin gene in WBS patients
      has been claimed to provide a biological basis for the abnormal elastic fibre properties
      leading to cardiovascular abnormalities like supravalvular aortic stenosis (SVAS),
      hypertension, arteriosclerosis and stenosis in more than 50% of WBS children.

      These cardiovascular pathologies result in important consequences and neither curative nor
      preventive medicinal treatments exist at this time. Surgery is needed in more than half
      cases, while it is often leading to complications.

      Minoxidil is a well-known antihypertensive drug used in adults and children. Furthermore,
      according to animal studies, minoxidil seems to increase arterial elastin content by
      decreasing elastase activity in these tissues. Other data demonstrate that minoxidil
      specifically stimulate elastin synthesis.

      Working Hypothesis:If insufficient elastin synthesis leads to vascular complications and
      arterial hypertension in children with WBS, restoration of sufficient quantity of elastin
      should then result in prevention or inhibition of vascular malformations and improvement in
      arterial tension. Therefore, as a pharmacological agent capable to stimulate elastin
      expression, minoxidil might be a useful drug for the treatment of abnormal elastin metabolism
      in WBS children.

      Objective:To evaluate the efficacy of minoxidil on cardiovascular structure in children with
      Williams Beuren syndrome.

      Methodology: randomized controlled trial on two parallel group (23 patients in each arm) Main
      criterion:variation of carotid Intima-media thickness (IMT) before and after 12 months of
      treatment with Minoxidil versus placebo Secondary intermediate criteria of the vascular
      properties are arterial stiffness, cardiac and renal stenosis, arterial tension.

      Total study duration:30 months including a 12 month-recruitment period
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of carotid Intima-media thickness (IMT) before and after 12 months of treatment with Minoxidil versus placebo (vascular echography at inclusion J0, M12).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of minoxidil on humeral IMT (vascular echography at J0, M12 and M18)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of minoxidil on arterial stiffness (pulse wave velocity and vascular compliance at J0, M12 and M18)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of minoxidil on supravalvular stenosis, pulmonary stenosis, aortic stenosis and renal stenosis (cardiac and renal echodoppler at J0, and M12)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of minoxidil on arterial tension (24H-Holter at J0 and M12)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of minoxidil on neurohumoral mechanisms of cardiovascular regulation and on plasmatic markers of the extracellular matrix.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic study: characterization of deletions responsible for WBS (size deletion, DNA sample at inclusion).</measure>
    <time_frame>inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Williams Beuren Syndrome</condition>
  <arm_group>
    <arm_group_label>Minoxidil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo = lactose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minoxidil</intervention_name>
    <description>Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.</description>
    <arm_group_label>Minoxidil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  proven diagnosis of Williams Beuren syndrome (genetic test)

          -  normotension or hypertension, treated or not

          -  male or female,

          -  6&lt; age &lt;18,

          -  negative pregnancy test for childbearing potential female

          -  effective birth control for sexually active female

          -  signed consent form collected from parents or legal guardian

        Exclusion Criteria:

          -  pulmonary hypertension secondary to mitral stenosis

          -  myocardial infarction within 1 month prior randomization

          -  known allergies to minoxidil or any of the components of lonoten.

          -  asthma

          -  renal failure (creatinine clearance &lt;40ml/min)

          -  no affiliation to a national health insurance program (social security)

          -  intolerance to lactose

          -  current vasodilator anti hypertensive treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Behrouz KASSAI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Cardiologie Pédiatrique, CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie, Hôpital Saint-André, CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie Pédiatrique, Hôpital Pellegrin, CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Génétique Médicale, Hôpital Pellegrin, CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Pédiatrie, Hôpital Femme Mère Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie Pédiatrique, Hôpital Cardiovasculaire L. Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service Cardiologie, CHU St Jacques</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Pédiatrie- Service de Cardiologie, CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie Pédiatrique, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Cardiovasculaires Infantiles et Congénitales, CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie Infantile, CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie Pédiatrique, Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Physiologie, Explorations Fonctionnelles, Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Pharmacologie Clinique, Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pathologie Cardiaque Congénitale du Fœtus, de l'Enfant et de l'Adulte, Hôpital Haut Lévêque, CHU de Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Génétique Médicale, CHU La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie - Hôpital des Enfants</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie Pédiatrique - Hôpital des Enfants, CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.autourdeswilliams.org</url>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Williams Beuren syndrome</keyword>
  <keyword>Cardiovascular abnormalities</keyword>
  <keyword>Cardiovascular structure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Williams Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

